Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Exact Sciences (EXAS – Research Report) today. The company’s shares closed last Friday at $73.20.
Nowak covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Guardant Health, and CVRx. According to TipRanks, Nowak has an average return of 0.8% and a 40.67% success rate on recommended stocks.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $92.80, which is a 26.78% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $100.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $100.77 and a one-year low of $53.89. Currently, Exact Sciences has an average volume of 1.61M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Numbers and CFO Transition
- Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
- Benchmark upgrades Exact Sciences to Buy, names best idea for 2024
- Exact Sciences upgraded to Buy from Hold at Benchmark
- Exact Sciences initiated with bullish view at Guggenheim, here’s why
